Cancer Care: NHIA Expands Insurance Cover, Slashes Drug Costs by 80%

In what marks one of the most substantial interventions in Nigeria's public healthcare financing in recent years, the National Health Insurance Authority (NHIA) has officially expanded its benefits package to cover up to 80 percent of cancer medication expenses for eligible enrollees across the federation.

The landmark policy is designed to drastically cushion the catastrophic out-of-pocket financial burden endured by oncology patients, whose lifesaving regimens regularly run into millions of naira monthly. Under the revised framework, eligible enrollees receiving chemotherapy and targeted therapeutic interventions at accredited tertiary health institutions will only bear 20 percent of their drug procurement costs, with the national insurer directly subsidising the remainder.

Oncology experts and patient advocacy organisations have long warned that non-communicable diseases—specifically breast, cervical, and prostate cancers—represent a silent economic catastrophe for Nigerian households. In an economy grappling with persistent inflation and currency depreciation that have driven pharmaceutical import costs to record highs, this intervention provides immediate, tangible relief to vulnerable families on the brink of financial ruin.

According to senior officials familiar with the implementation blueprint, the subsidy will be routed through verified oncology treatment centres across the six geopolitical zones, guaranteeing that authenticated medication batches are dispensed directly to insured patients without bureaucratic bottlenecks.